Vivos Therapeutics (VVOS) Competitors $6.74 -0.21 (-3.02%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$6.64 -0.10 (-1.42%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VVOS vs. ELMD, RCEL, LNSR, PDEX, BSGM, KRMD, PTHL, LAKE, LUCD, and INFUShould you be buying Vivos Therapeutics stock or one of its competitors? The main competitors of Vivos Therapeutics include Electromed (ELMD), Avita Medical (RCEL), LENSAR (LNSR), Pro-Dex (PDEX), Biosig Technologies (BSGM), KORU Medical Systems (KRMD), Pheton (PTHL), Lakeland Industries (LAKE), Lucid Diagnostics (LUCD), and InfuSystem (INFU). These companies are all part of the "medical equipment" industry. Vivos Therapeutics vs. Its Competitors Electromed Avita Medical LENSAR Pro-Dex Biosig Technologies KORU Medical Systems Pheton Lakeland Industries Lucid Diagnostics InfuSystem Electromed (NYSE:ELMD) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations. Do institutionals & insiders have more ownership in ELMD or VVOS? 40.8% of Electromed shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 14.0% of Electromed shares are owned by insiders. Comparatively, 3.0% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend ELMD or VVOS? Electromed currently has a consensus target price of $38.00, suggesting a potential upside of 108.33%. Vivos Therapeutics has a consensus target price of $4.82, suggesting a potential downside of 28.54%. Given Electromed's stronger consensus rating and higher possible upside, analysts clearly believe Electromed is more favorable than Vivos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Electromed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Vivos Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is ELMD or VVOS more profitable? Electromed has a net margin of 11.34% compared to Vivos Therapeutics' net margin of -76.82%. Electromed's return on equity of 15.71% beat Vivos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Electromed11.34% 15.71% 13.37% Vivos Therapeutics -76.82%-170.43%-77.82% Which has better earnings & valuation, ELMD or VVOS? Electromed has higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElectromed$61.44M2.49$5.15M$0.7923.09Vivos Therapeutics$15.03M2.64-$11.14M-$1.73-3.90 Does the media refer more to ELMD or VVOS? In the previous week, Vivos Therapeutics had 1 more articles in the media than Electromed. MarketBeat recorded 1 mentions for Vivos Therapeutics and 0 mentions for Electromed. Vivos Therapeutics' average media sentiment score of 1.87 beat Electromed's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Electromed Neutral Vivos Therapeutics Very Positive Which has more volatility and risk, ELMD or VVOS? Electromed has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.01, indicating that its share price is 601% more volatile than the S&P 500. SummaryElectromed beats Vivos Therapeutics on 12 of the 17 factors compared between the two stocks. Get Vivos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VVOS vs. The Competition Export to ExcelMetricVivos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.93M$2.44B$5.61B$9.29BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-3.909.1428.5419.58Price / Sales2.64679.15429.2495.01Price / CashN/A164.3436.0257.93Price / Book4.994.608.145.54Net Income-$11.14M$30.99M$3.24B$257.73M7 Day Performance12.33%-1.81%0.18%-0.08%1 Month Performance202.24%5.73%5.96%8.09%1 Year Performance134.03%-7.03%26.24%13.02% Vivos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VVOSVivos Therapeutics1.3027 of 5 stars$6.74-3.0%$4.82-28.5%+141.6%$40.93M$15.03M-3.90160Positive NewsELMDElectromed0.8626 of 5 stars$19.30+1.2%$38.00+96.9%+20.2%$161.85M$61.44M25.73160RCELAvita Medical1.3532 of 5 stars$5.88+3.2%$16.50+180.6%-45.7%$155.41M$64.25M-2.68130Positive NewsLNSRLENSAR1.295 of 5 stars$12.90-1.0%$15.00+16.3%+150.5%$152.09M$53.49M-2.66110Positive NewsPDEXPro-Dex2.4899 of 5 stars$46.23+2.7%$56.00+21.1%+144.1%$150.71M$53.84M16.51140Positive NewsHigh Trading VolumeBSGMBiosig Technologies1.9052 of 5 stars$5.46+4.4%$10.00+83.2%+955.3%$149.06M$40K0.0050News CoverageGap UpHigh Trading VolumeKRMDKORU Medical Systems2.7206 of 5 stars$3.22-7.5%$4.50+39.8%+17.6%$148.57M$33.65M-29.2780PTHLPhetonN/A$21.52+2.4%N/AN/A$141.60M$450K0.0011High Trading VolumeLAKELakeland Industries4.8436 of 5 stars$13.78-3.7%$26.00+88.7%-40.4%$131.12M$177.65M-4.582,100Positive NewsHigh Trading VolumeLUCDLucid Diagnostics2.6017 of 5 stars$1.17+2.6%$3.55+203.4%+32.9%$126.58M$4.17M-0.8770News CoveragePositive NewsINFUInfuSystem3.1169 of 5 stars$5.61-3.3%$13.00+131.7%N/A$117.90M$137.58M93.52410 Related Companies and Tools Related Companies Electromed Competitors Avita Medical Competitors LENSAR Competitors Pro-Dex Competitors Biosig Technologies Competitors KORU Medical Systems Competitors Pheton Competitors Lakeland Industries Competitors Lucid Diagnostics Competitors InfuSystem Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VVOS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VVOS Stock Alerts